ArticleCellular immunology2015
HBD-3 induces NK cell activation, IFN-γ secretion and mDC dependent cytolytic function.
Article in Cellular immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- β-defensin-3 promoted osteosarcoma progression via activating the PI3K/AKT pathway and regulated tumor immune response.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Characterization of Tissue Immunity Defense Factors of the Lip in Primary Dentition Children with Bilateral Cleft Lip Palate.Journal of personalized medicine · 2024Article
- Local Defense Factors in Cleft-Affected Palate in Children before and during Milk Dentition Age: A Pilot Study.Journal of personalized medicine · 2023Article
- Application Value of Antimicrobial Peptides in Gastrointestinal Tumors.International journal of molecular sciences · 2023Review
- A computational approach to design a polyvalent vaccine against human respiratory syncytial virus.Scientific reports · 2023Article
- Human β-Defensin-3 is Associated With Platelet-Derived Extracellular Vesicles and is a Potential Contributor to Endothelial Dysfunction.Frontiers in molecular biosciences · 2022Article
- Designing a multi-epitope vaccine to provoke the robust immune response against influenza A H7N9.Scientific reports · 2021Article
- Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis.Infection and drug resistance · 2020Article
- The Dichotomous Responses Driven by β-Defensins.Frontiers in immunology · 2020Review
- HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines.Antibiotics (Basel, Switzerland) · 2019Article
- Multifaceted immune functions of human defensins and underlying mechanisms.Seminars in cell & developmental biology · 2019Review
- Overexpressing ovotransferrin and avian β-defensin-3 improves antimicrobial capacity of chickens and poultry products.Transgenic research · 2019Article
- Identification of compound-protein interactions through the analysis of gene ontology, KEGG enrichment for proteins and molecular fragments of compounds.Molecular genetics and genomics : MGG · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
We previously showed that human beta defensin-3 (hBD-3) activates mDC via TLR1/2. Here we investigated the effects of hBD-3 on NK cell activation state and effector functions. We observed that hBD-3 activates PBMC to secrete IFN-γ and kill K562 and HUH hepatoma target cells in an NK dependent fashion, and both TLR1/2 and CCR2 are involved. TLR1, TLR2 and CCR2 were expressed on NK cells, and in purified NK culture experiments we observed hBD-3 to directly act on NK cells, resulting in CD69 upregulation and IFNγ secretion. We also observed mDC-hBD-3 enhanced NK cytolytic activity and IFNγ production. These results implicate hBD-3 in its ability to directly activate NK cells and increase NK cell effector function, as well as promote mDC-dependent NK activity. HBD-3 may therefore act as a mediator of innate cell interactions that result in bridging of innate and adaptive immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.